Vaccine portfolio optimization: Guidance, tools, and resources for evidence-based decision making

Countries now have access to an unprecedented wave of new vaccine options — alternative presentations, products, and schedules, as well as new vaccines in the pipeline. This expanding landscape provides an opportunity to examine the full vaccine portfolio and identify ways to improve coverage and impact, reduce costs and wastage, and lessen the burden on the cold chain and on health workers. Each switch comes with trade-offs, making it crucial that countries assess their priorities and weigh available evidence and programmatic factors for each option.

 

As countries begin to explore ways to optimize the EPI portfolio — whether to identify options better suited to their context, navigate supply challenges, or make space for new introductions — and consider new vaccine introductions, new and growing bodies of guidance, evidence, and experiences can help inform those discussions. 

 

This page provides a compendium of tools, guidance documents, and case studies to support countries in navigating available and upcoming vaccine options and making evidence-based decisions to optimize the cost, impact, logistics or programmatic ease of their vaccine portfolio and prioritize new vaccine decisions.

 

Note: This site is currently under revision and information below may not be up to date. Additional resources, including the Vaccine Prioritization and Portfolio Optimization (VPOP) toolkit and the New Vaccine Introduction Prioritization and Sequencing Tool (NVI-PST), are available on the Global NITAG Network (GNN) NITAG Resource Website.